TransCode Therapeutics Reports Pricing Of $7M Public Offering
Portfolio Pulse from Benzinga Newsdesk
TransCode Therapeutics announced the pricing of its $7M public offering, consisting of 2,000,000 shares of common stock and accompanying warrants at $3.50 per share.
June 06, 2023 | 9:33 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
TransCode Therapeutics' $7M public offering may impact RNAZ's stock price in the short term.
TransCode Therapeutics' public offering announcement directly affects RNAZ as it is the company's stock symbol. The pricing of the offering at $3.50 per share may influence investor sentiment and trading activity, potentially impacting the stock price in the short term. However, the exact direction of the impact is uncertain.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100